Pregnant women diagnosed with gestational diabetes mellitus subjected to diet (GDMd) that do not reach normal glycaemia are passed to insulin therapy (GDMi). GDMd associates with increased human cationic amino acid transporter 1 (hCAT-1)-mediated transport of L-arginine and nitric oxide synthase (NOS) activity in foetoplacental vasculature, a phenomenon reversed by exogenous insulin. Whether insulin therapy results in reversal of the GDMd effect on the foetoplacental vasculature is unknown. We assayed whether insulin therapy normalizes GDMd-associated foetoplacental endothelial dysfunction. Primary cultures of human umbilical vein endothelial cells (HUVECs) from GDMi pregnancies were used to assay L-arginine transport kinetics, NOS activity, p44/ 42 mapk and protein kinase B/Akt activation, and umbilical vein rings reactivity. HUVECs from GDMi or GDMd show increased hCAT-1 expression and maximal transport capacity, NOS activity, and eNOS, and p44/42 mapk , but not Akt activator phosphorylation. Dilation in response to insulin or calcitonin-gene related peptide was impaired in umbilical vein rings from GDMi and GDMd pregnancies. Incubation of HUVECs in vitro with insulin (1 nmol/L) restored hCAT-1 and eNOS expression and activity, and eNOS and p44/42 mapk activator phosphorylation. Thus, maternal insulin therapy does not seem to reverse GDMd-associated alterations in human foetoplacental vasculature.
Introduction
Gestational diabetes mellitus (GDM) is a disease of pregnancy that characterizes by abnormal maternal D-glucose metabolism and altered insulin signalling in the foetoplacental circulation [1] [2] [3] [4] [5] . GDM-associated alterations lead to foetal hyperglycaemia and hyperinsulinemia resulting in endothelial dysfunction, and abnormal placental development and foetal growth [5, 6] . Pregnant women that develop GDM are subjected to controlled diet (GDMd pregnancies) to reduce glycaemia to the recommended goals [1, 4, 7] . However, a fraction of these women does not reach normal glycaemia with diet and are passed to treatment with insulin (i.e., insulin therapy, GDMi pregnancies) until delivery [3, 4, [8] [9] [10] . Both the mother and newborns in GDMd and GDMi pregnancies show with normal glycaemia at term [11] [12] [13] . However, the foetoplacental endothelial cell function and vascular reactivity are altered in GDMd [3, 5, 13] .
Increased expression and activity of the endothelial nitric oxide synthase (eNOS) and uptake of the amino acid L-arginine via the human cationic amino acid transporter 1 (hCAT-1), an isoform of human cationic amino acids transporters (hCATs) family [14, 15] , is reported in human umbilical vein endothelial cells (HUVECs) from GDMd pregnancies [13, 16] . Exposure of HUVECs in vitro to physiological concentrations of insulin (up to 1 nmol/L) reverses the effects of GDMd on L-arginine transport [13] and NO synthesis [16] . Interestingly, high extracellular D-glucose (~25 mmol/L) also increases L-arginine transport via hCAT-1 and NO synthesis in HUVECs from normal pregnancies suggesting that hyperglycaemia could cause these changes in endothelial function [17] . Since insulin therapy results in normalization of the glycaemia in the mother and newborn at birth [4, 9, 18, 19] , a reversal of the effects of GDMd in the foetoplacental endothelial function is likely. In this study, we assayed whether maternal insulin therapy reverses the effects seen in GDMd on HUVECs function at birth. The results suggest that insulin therapy is not enough to reverse the foetoplacental endothelial dysfunction seen at birth in normoglycaemic, diet-controlled women with GDM.
Material and methods

Antibodies and materials
Primary monoclonal mouse anti-hCAT-1 and anti-ß-actin antibodies were from Sigma Aldrich (St Louis, MO, USA). Primary monoclonal mouse anti-eNOS phosphorylated at serine 1177 , polyclonal rabbit antitotal p44/42 mapk , anti-phosphorylated p44/42 mapk , anti-total Akt and anti-phosphorylated Akt antibodies were from Cell Signaling Technology (Danvers, MA, USA). Primary monoclonal mouse anti-eNOS phosphorylated at threonine 495 antibody was from BD Transduction Laboratories (San Jose, CA, USA). Primary monoclonal mouse anti-total eNOS antibody and secondary horseradish peroxidase-conjugated goat anti-rabbit or anti-mouse antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). For isolation of HUVECs from umbilical cords Collagenase Type II from Clostridium histolyticum (Boehringer, Mannheim, FRG) was used. Medium M199, new born (NBCS) and fetal calf (FCS) sera, L-glutamine, and penicillin-streptomycin were from Gibco Life Technologies (Carlsbad, CA, USA). L- . N G -Nitro-L-arginine methyl ester (L-NAME) and calcitonine gene related peptide (CGRP) were from Sigma Aldrich, and Akt Inhibitor IV (Inh-IV) and PD-98059 from Calbiochem (La Jolla, CA, USA). Immobilon-P polyvinylidene difluoride membranes was from BioRad Laboratories (Hertfordshire, UK). Qiagen RNAeasy kit was from Qiagen (Crawley, UK) and brilliant SYBR green qPCR Master Mix from Stratagene (La Jolla, CA, USA). The fluorescent dye 4-amino-5-methylamino-2′,7′-difluorofluorescein (DAF-FM) was from Molecular Probes (Leiden, The Netherlands).
Study groups
This study included samples collected from 13 full-term normal or 32 full-term GDM pregnancies from the Hospital Clínico UC-CHRISTUS (HCUC-C) and Hospital San Juan de Dios (HSJD) in Santiago de Chile. Pregnant women included in this study did not smoke or consume drugs or alcohol, and had no intrauterine infection or any other medical or obstetrical complications. Ethnicity of patients included in this study was Hispanic. The investigation conforms to the principles outlined in the Declaration of Helsinki. Ethics Committee approvals from the Faculty of Medicine of the Pontificia Universidad Católica de Chile and HSJD, and informed written consent of patients were obtained. All pregnant women with a normal glycaemia at the first trimester of pregnancy were evaluated by an oral glucose tolerance test (OGTT) with a unique glucose load (75 g fasting) at 24-28 weeks of gestation. Patients with basal glycaemia ≥ 5.56 (≥ 100 mg/dL, 8-9 h from last feeding in at least two different days) and with ≥7.9 mmol/L (≥ 140 mg/dL) at 2 h after glucose load at the second or third trimester of pregnancy were diagnosed with GDM (according to the Perinatal Guide 2015 report from the Health Ministry of Chile) [20] . Weight and body mass index (BMI) were recorded before pregnancy (i.e., pre-gestational) and for each trimester of pregnancy and at term.
Three groups of pregnant women were included in this study, i.e., normal pregnancies (n = 13), GDMd pregnancies (n = 14), or GDMd pregnancies where the mother was treated with insulin (GDMi, i.e., on insulin therapy) (n = 18). Qualified personnel of the HCUC-C and HSJD selected the groups of pregnant women according to their clinical characteristics following established protocols. Women coursing with normal pregnancies followed standard self-controlled diet and physical activity. Women with GDMd were subjected to dietary treatment with 1500 kcal/day and a maximum of 200 g per day carbohydrates. Plasma glucose was weekly measured at fasting and post-breakfast, before and 1 h after the midday and evening meals. Women with GDMd that did not reach normal glycaemia after two weeks of diet were passed into insulin therapy following protocols adopted at the Division of Obstetrics and Gynaecology at the HCUC-C and HSJD as recommended in the Perinatal Guide 2015 Chile [20] . In brief, women with GDMd not responsive to diet were treated for 8-10 weeks until delivery with two injections (one before breakfast and one at bedtime) of neutral protamine Hagerdon human insulin (Humulin-N or Insuman-N, 0.5-0.65 units/kg of pre-pregnancy body weight). Additional three injections of regular (rapid-acting) insulin (Humulin-R or Insuman-R) depending on pre-prandial self-controlled capillary glycaemia (0.1 to 6 units/kg per meal for 81-120 to > 250 mg/dL glucose, respectively) were administered to women with GDMd as described for insulin therapy in pregnant women with pre-gestational diabetes mellitus type 1 or 2 [11, 21] .
Human placenta and umbilical cords
Placentas were collected at delivery on ice and transferred to the laboratory until use 15-30 min later. Middle sections of umbilical cords (100-120 mm length) were dissected into 200 mL phosphate-buffered saline (PBS) solution (mmol/L: 130 NaCl, 2.7 KCl, 0.8 Na 2 HPO 4 , 1.4 KH 2 PO 4 , pH 7.4, 4°C) until use 6-12 h later for isolation of endothelial cells.
Cell culture
HUVECs were isolated by collagenase digestion (0.25 mg/mL collagenase) from umbilical cords obtained at birth from normal, GDMd, or GDMi pregnancies and cultured (37°C, 5% CO 2 ) in 1% gelatincoated petri dishes (100 mm diameter) up to passage 3 in primary culture medium (PCM; M199 containing 5 mmol/L D-glucose, 10% NBCS, 10% FCS, 3.2 mmol/L L-glutamine and 100 U/mL penicillinstreptomycin). 16 h prior experiments the incubation medium was changed to M199 medium containing 0.25% NBCS and 0.25% FCS. Experiments were performed in the absence (hereafter referred as 'without insulin') or presence (8 h, hereafter referred as 'with insulin') of insulin (1 nmol/L), L-NAME (100 μmol/L, NOS inhibitor) [22] , Inh-IV (1 μmol/L, protein kinase B/Akt inhibitor) [23] , and/or PD-98059 (10 μmol/L, MAP kinase kinases 1/2 inhibitor) [24] . [13] . Cell monolayers were rinsed with ice-cold Krebs to terminate tracer uptake. Initial rate for transport (i.e., linear uptake up to 1 min) was derived from the slope of the linear phases of L-arginine transport. Values for transport were adjusted to the one phase exponential association equation considering the least squares fit:
L-Arginine transport
where v i is initial velocity, V m is mayor velocity at a given time (t) and Larginine concentration, and e and k are constants. Overall L-arginine transport at initial rates was adjusted to the Michaelis-Menten hyperbola plus a nonsaturable, linear component (K D ) as described [13] . The saturable transport of L-arginine was derived by subtracting the m · [Arg] components from overall transport, and the transport kinetic parameters maximal velocity (V max ) and apparent Michaelis-Menten constant (K m ) of transport were calculated [13] . The relative contribution of GDMd, GDMi, insulin, PD-98059, or Inh-IV to the saturable L-arginine transport kinetic parameters was estimated from the maximal transport capacity (V max /K m ) values for L-arginine transport by: 
Western blotting
Total protein was obtained from confluent cells washed twice with ice-cold PBS and harvested in 100 μL of lysis buffer composed by 63.7 mmol/L Tris/HCl (pH 6.8), 10% glycerol, 2% sodium dodecylsulphate (SDS), 1 mmol/L sodium orthovanadate, 50 mg/mL leupeptin, and 5% 2-mercaptoethanol, as described [13] . Cells were sonicated (6 cycles, 5 s, 100 W, 4°C), and total protein was separated by centrifugation (14,000g, 15 min, 4°C). Proteins (70 μg) were separated by polyacrylamide gel (10%) electrophoresis and transferred onto Immobilon-P polyvinylidene difluoride membranes. The proteins were then probed against hCAT-1 (1:500 dilution, 12 h, 4°C), total eNOS 
Isolation of total RNA and reverse transcription
Total RNA was isolated using the Qiagen RNAeasy kit. RNA quality and integrity were insured by gel visualization and spectrophotometric analysis (OD 260 / 280 ), quantified at 260 nm. Aliquots (2 μg) of total RNA were reversed transcribed into cDNA as described [13] .
Quantitative RT-PCR
Experiments were performed using a StepOne Real-Time PCR system (Applied Biosystems, Foster City, CA, USA) in a reaction mix containing 0.5 μmol/L primers, and master mix provided in the brilliant SYBR green qPCR Master Mix as described [13] . SecureStartTaq DNA polymerase was activated (15 min, 95°C), and the PCR cycling profile included a 95°C denaturation (15 s 
NOS activity
NOS activity was assayed by quantification of the intracellular content of L-citrulline by high performance liquid chromatography in confluent HUVECs in the absence or presence of 100 μmol/L L-NAME, as reported [17] .
Human umbilical vein reactivity
Ring segments of 2-4 mm in length were dissected from human umbilical veins in ice-cold PBS (pH 7.4, 4°C). Vein rings were mounted in a myograph (610M Multiwire Myograph System, Danish Myo Technology A/S, Denmark) for isometric force measurements in a Krebs physiological solution (mmol/L: 118.5 NaCl, 4.7 KCl, 25 NaHCO 3 , 1.2 MgSO 4 , 1.2 KH 2 PO 4 , 2.5 CaCl 2 , 5.5 D-glucose, 0.3 L-arginine, 37°C, pH 7.4). Vein rings were constantly bubbled with a mixture of 95% O 2 / 5% CO 2 . The optimal diameter for each vessel was adjusted through the determination of the maximal active response evoked by 65 mmol/L KCl [13] . Endothelium-dependent relaxation was evaluated as the concentration-dependent response to CGRP (0.01 − 100 nmol/L, 5 min) and insulin (0.01− 1000 nmol/L, 5 min) in KCl-preconstricted vessels. Experiments were performed in the absence or presence of 100 μmol/L L-NAME. Changes in isometric tension were recorded using the software LabChart (LabChart 7 for Windows, ADInstruments, Australia) coupled to a PowerLab (PowerLab 8/30 Data Acquisition System, ADInstruments, Australia).
Statistical analysis
The sample size was estimated considering a power of 80% to detect a difference between groups (on the basis of a two-sided alpha level of 0.05). Values for clinical parameters are given as mean ± S.D. For in vitro assays the values were mean ± S.E.M., where n indicates number of different biological samples and corresponding cell cultures with 3-4 replicates per experiment. Comparisons between two groups were performed by means of Student's unpaired t-test and between more than two groups by analysis of variance (ANOVA, two-ways). If the ANOVA demonstrated a significant interaction between variables, post hoc analyses were performed by the multiple-comparison Bonferroni test. The statistical software GraphPad InStat 3.1 and GraphPad Prism 7.0c (GraphPad Software Inc., San Diego, CA, USA) was used for data analysis. P < 0.05 was considered statistically significant.
Results
Study groups
Pregnancies were singleton, and pregnant women showed with similar age and height, were normotensive, and with normal fasting glycaemia at term ( Table 1 ). The total gestational weight gain between pre-pregnancy and term was 10 ± 1 kg in normal pregnancies, 8.9 ± 0.9 kg in GDMd pregnancies, and 9.9 ± 1.1 kg in GDMi pregnancies. Clinical parameters of newborns from the three study groups did not show significant differences.
L-Arginine transport kinetics
The v i for overall 100 μmol/L L-arginine transport was lineal up to 60 s in cells from normal, GDMd, or GDMi pregnancies without insulin (Fig. 1A) . Values for v i were higher in cells from GDMd and GDMi compared with normal pregnancies (Table 2 ). Overall L-arginine transport was semisaturable in cells without insulin from normal, GDMd, or GDMi pregnancies (Fig. 1B) , with K D values higher in GDMd and GDMi compared with normal pregnancies (Table 2 ). After substracting the lineal, non-saturable transport component from overall transport, the remaining L-arginine transport was saturable, best fitted by a single Michaelis-Menten equation (Fig. 1C) , and lineal in an EadieHofstee plot (Fig. 1D) . Saturable transport showed with higher V max in cells from GDMd and GDMi compared with normal pregnancies. The apparent K m values were not significantly altered in cells from these three study groups. However, the maximal transport capacity (V max / K m ) was higher in GDMd and GDMi when compared with normal pregnancies (Table 2) .
Insulin increased the v i and K D in cells from normal pregnancies, but restored this parameter in GDMd and GDMi (Fig. 1E) . Overall transport in the presence of insulin was also semisaturable (Fig. 1F) , and saturable transport showed higher V max and V max /K m , but unaltered K m values in cells from normal pregnancies (Fig. 1G ). GDMd and GDMiincreased L-arginine transport was blocked by insulin. Eadie-Hofstee plot of saturable data was lineal in cells treated with insulin from all study groups (Fig. 1H ).
hCAT-1 protein abundance and mRNA expression
In cells without insulin the hCAT-1 protein abundance was higher in GDMd and GDMi compared with normal pregnancies (Fig. 2A) . Incubation of cells with insulin, increased hCAT-1 protein abundance in normal pregnancies, but partially reduced its abundance in GDMd and GDMi. Similar results were obtained for hCAT-1 mRNA expression without or with insulin; however, insulin fully reversed GDMd effect (Fig. 2B) .
Involvement of p44/42
mapk and Akt on L-arginine transport
Cells from GDMd and GDMi without insulin show increased p44/ 42 mapk phosphorylation compared with normal pregnancies (Fig. 3A) .
Insulin blocked the GDMd and GDMi effect, but increased p44/p42 mapk phosphorylation in cells from normal pregnancies. Phosphorylated Akt protein abundance was unaltered by GDMd or GDMi, or insulin in cells from normal or GDM pregnancies. IR-A mRNA expression was higher in cells from GDMd and GDMi compared with normal pregnancies (Fig. 3B) . Insulin blocked GDM effect on IR-A mRNA expression, but unaltered its expression in cells from normal pregnancies. However, IR-B mRNA expression was unaltered by GDM or insulin. Women that coursed with normal pregnancies (Normal), GDM under treatment with diet (GDMd) or GDMd passed onto insulin therapy (GDMi) were included in this study. Weight, body mass index (BMI), and blood pressure were determined before pregnancy (pre-pregnancy) and at 1st (0-14 weeks of gestation (wg)), 2nd (14-28 wg) or 3th (28-40 wg) trimesters of pregnancy and at term (38-41 wg). Values for pre-pregnancy weight and blood pressure correspond to those autoreferred by patients. In Normal pregnancies, 11 women were with pre-pregnancy normal weight (BMI < 25 kg/m 2 ) and two with pre-pregnancy overweight (BMI ≥ 25 and < 30 kg/m 2 ). In GDMd, 11 women were with pre-pregnancy normal weight, two pre-pregnancy overweight, and one prepregnancy obese (BMI ≥ 30 kg/m 2 ). In GDMi, 14 women were with pre-pregnancy normal weight, two pre-pregnancy overweight, and two pre-pregnancy obese. BMI was calculated by weight in kilograms divided by the square of the height in meters. Ponderal index was calculated by weight in grams divided by the cube of height in centimeters multiplied by 100. Oral glucose tolerance test (OGTT) was measured at 24-28 weeks of gestation in all women with a normal glycaemia (see Material and methods). Values are mean ± S.D.
⁎ P < 0.05 versus corresponding values in Normal. M. Subiabre et al.
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Overall L-arginine transport in the presence of PD-98059 and Inh-IV was semisaturable as in the absence of these inhibitors (not shown). Incubation of cells with PD-98059, Inh-IV, or both, did not alter the v i or K D values in cells from normal pregnancies without insulin (Table 2) . However, insulin-stimulatory effect on these parameters was blocked by PD-98059 or PD-98059 + Inh-IV, but unaltered by Inh-IV alone. Insulin-increased V max and V max /K m for saturable transport was blocked by PD-98059 or PD-98059 + Inh-IV; however, Inh-IV alone blocked the increase caused by insulin in the V max /K m , but not in V max (Fig. 3C , Table 2 ). In cells without insulin the GDMd-increased v i and V (Table 2 ). In cells with insulin the pattern of effects of the inhibitors in the kinetic parameters was similar compared to those in cells from GDMd, except for Inh-IV which inhibits the increase in v i caused by GDMi.
NOS activity
The intracellular content of L-citrulline generated by NOS activity (i.e., fraction inhibited by L-NAME) was higher reaching similar values in cells from GDMi and GDMd, compared with normal pregnancies (Fig. 4A ). Insulin caused a substantial reduction in GDM-increased Lcitrulline content, but increased intracellular content of this amino acid in cells from normal pregnancies. In addition, the NO level detected in cells from GDMd and GDMi was higher than normal pregnancies (Fig. 4B) . Insulin increased NO level in cells from normal pregnancies, and partially reversed the effect of GDM. Table 2 Kinetic parameters for L-arginine transport in HUVECs from normal or GDM pregnancies.
Saturable transport
Overall transport 
eNOS expression and phosphorylation
Cells from GDMd and GDMi without insulin show comparable higher eNOS protein abundance compared with normal pregnancies (Fig. 4C) . Insulin partially reduced GDM effect on eNOS, but increased its protein abundance in cells from normal pregnancies. In cells without insulin the P-Ser 1177 eNOS protein abundance was higher in GDM pregnancies reaching similar values, an effect blocked by insulin in cells from GDMd, but partially reversed by this hormone in GDMi (Fig. 4D ). Insulin increased P-Ser 1177 eNOS protein abundance in cells from normal pregnancies. However, neither GDM nor insulin altered PThr 496 eNOS protein abundance (Fig. 4E ). GDMd and GDMi associated with higher and comparable eNOS mRNA expression (Fig. 4F ) compared with cells from normal pregnancies. Insulin reversed the GDM effect on eNOS mRNA, but increased mRNA expression in cells from normal pregnancies.
Umbilical vein reactivity
Insulin caused concentration, NOS-dependent relaxation in umbilical vein rings (Fig. 5A ). Maximal relaxation (R max ) in response to insulin was lower, but half-maximal effect (EC 50 ) was higher in vein rings from GDMd and GDMi compared with normal pregnancies (Table 3) . The required insulin concentration to cause a similar R max (i.e., EC 50 / R max ) was higher in GDMd and GDMi compared with normal pregnancies. The EC 50 /R max was higher in GDMi compared with vessel rings from GDMd. CGRP also caused concentration-dependent relaxation of vein rings (Fig. 5B) with an EC 50 values lower than those for insulin effect in vessel rings from all conditions ( Table 3 ). The EC 50 in vein rings from GDMd was lower than vessel rings from normal or GDMi pregnancies, but higher in samples from GDMi (Table 3 ). The R max in response to CGRP was similar than in response to insulin in normal pregnancies. The EC 50 /R max values for CGRP were higher in GDMd and GDMi compared with normal pregnancies, higher in GDMi compared with GDMd pregnancies. In addition, the EC 50 /R max values for CGRP were higher for vessel rings from all pregnancies.
Discussion
This study shows for the first time that HUVECs from pregnancies where the mother with GDMd was subjected to insulin therapy (GDMi) exhibit increased L-arginine transport and NO synthesis, which was comparable to cells from GDMd without insulin therapy or from normal pregnancies exposed to insulin in vitro. Cells from GDMi show increased p44/42 mapk activation and IR-A mRNA expressiom, but unaltered Akt activation and IR-B expression. Insulin in vitro reversed GDMi effect on L-arginine transport, NO synthesis and p44/42 mapk activation. NO and endothelium-dependent dilation of umbilical vein rings from GDMi was reduced in response to insulin compared with GDMd or normal pregnancies. Mothers and newborns from GDMi showed with normoglycaemia at term, but insulin therapy seems not enough to restore associated foetoplacental vascular dysfunction. GDM associates with reduced foetoplacental vascular reactivity due to microvascular [26] and macrovascular [12, 13, 16] endothelial dysfunction [5, 6] . HUVECs from women with GDMd (i.e., without insulin therapy) show increased L-arginine transport mediated by hCAT-1 [13] and NO synthesis due to eNOS activation [16] compared with normal pregnancies. Incubation of HUVECs from GDMd with insulin in vitro reversed the increased transport of L-arginine (half-maximal effective dose (ED 50 )~0.3 nmol/L) [27] and NO synthesis (ED 50~0 .4 nmol/L) [12] seen in this condition. Our results show that HUVECs from GDMi pregnancies exhibit similar changes to those in GDMd pregnancies. Thus, insulin therapy does not restores GDMd-associated human umbilical vein endothelial dysfunction. L-Arginine transport is mainly mediated by hCAT-1 with an apparent K m~1 00-200 μmol/L in HUVECs from normal pregnancies [28] [29] [30] , a value close to the concentration of this amino acid in the human umbilical vein blood (~80 μmol/L) [31, 32] . Thus, hCAT-1 plays a crucial role in the uptake of L-arginine in HUVECs. Saturable L-arginine transport in HUVECs from GDMi, and GDMd pregnancies shows apparent K m within hCAT-1 range. Furthermore, hCAT-1 protein and mRNA expression were higher in HUVECs from GDMi and GDMd compared with normal pregnancies. Thus, hCAT-1 is likely involved in the removal of L-arginine from the extracellular medium, and GDMi or GDMd unaltered this membrane transporter's intrinsic properties. hCAT-2B, another member of hCATs family [14, 15] , is coexpressed with hCAT-1 in HUVECs [33] mediating L-arginine transport with K m~3 00-400 μmol/L [14, 15] . Therefore, hCAT-2B may also mediate L-arginine transport in HUVECs from GDMi pregnancies. However, since Eadie-Hofstee plot of saturable transport and overall transport up to 250 μmol/L L-arginine were lineal, it is likely that a single membrane transport system in the range of 100-200 μmol/L (likely hCAT-1), or more than one transport system with K m within this range, accounted for uptake of L-arginine into HUVECs. hCAT-1 involvement on GDMi and GDMd-increased transport is further supported by the results showing that hCAT-1 protein abundance and mRNA expression was higher (~5 fold) in cells from GDMi and GDMd compared with normal pregnancies. Thus, increased L-arginine transport may result from higher hCAT-1 availability in HUVECs. Since the V max increase in GDMi and GDMd versus normal pregnancies was~2.6 and~3.2 fold, respectively, and because these conditions caused similar increase in hCAT-1 expression, a fraction not larger than 36-50% may be due to a change in hCAT-1 expression or availability at the plasma membrane in HUVECs from GDMi and GDMd.
The V max and V max /K m values in GDMi were similar to those in GDMd pregnancies, but higher compared with normal pregnancies. Thus, insulin therapy does not result in reversal of hCAT-1-mediated maximal transport capacity in HUVECs from GDM pregnancies. Since the increase in V max /K m was similar in GDMi and GDMd, but GDMi caused lower increase in V max compared with GDMd ( GDMi V max / GDMd V max~0 .7), different component(s) to those in GDMd may modulate Larginine transport in cells from GDMi pregnancies. Interestingly, overall L-arginine transport for values > 250 μmol/L showed higher K D for GDMi compared with GDMd (~1.43 fold) and normal pregnancies (~5.5 fold). Thus, along with hCAT-1, L-arginine uptake seems mediated via a transport system(s) that does not gets saturated up to 1000 μmol/L in cells from GDMi and GDMd pregnancies. Since apparent K m for hCAT-3, member of hCATs family [14, 15] , is > 500 μmol/L [34] , these transporters may be involved in overall L-arginine transport playing a minor contribution at < 250 μmol/L L-arginine in HUVECs.
Phosphorylation of p44/42 mapk was increased, but Akt phosphorylation was unaltered in cells from GDMi compared with normal pregnancies or in HUVECs from women with GDM not separated by diet only versus diet plus insulin therapy (GDMpool) [28] . [5, 12, 16] . All together these findings highlight potential differences on L-arginine transport modulation in HUVECs from these two conditions of pregnancy. Previous studies show increased eNOS activity in HUVECs from GDMpool [28, 35] or GDMd [16] pregnancies compared with normal pregnancies. We extended these observations to GDMi pregnancies where higher NO level and NOS activity was found, a phenomenon likely due to higher activator Ser 1177 phosphorylation of eNOS [36, 37] . Since eNOS protein abundance and mRNA expression were also increased in cells from these conditions, increased eNOS expression, reduced degradation or increased stability of eNOS protein or mRNA are alternative mechanisms that may be involved in this phenomenon. Insulin restored the V max /K m of transport by reducing the V max in cells from GDMi to values in normal pregnancies, confirming previous results in cells from GDMpool [28] or GDMd [13] pregnancies. Since the K m was not changed by insulin, it is likely hCAT-1 affinity for L-arginine uptake is unaltered by this hormone in cells from GDMi pregnancies. However, since GDMi-increased K D and v i was reversed by insulin, this hormone may restore the functionality of an alternative mechanism, potentially hCAT-3, for L-arginine transport. Since insulin also restored GDMi-increased hCAT-1 expression, this hormone may regulate hCAT-1 bioavailability in HUVECs from GDMi pregnancies. The contribution of a reduced hCAT-1 protein abundance to the lower V max /K m for transport caused by insulin in GDMi is partial since not more than two-thirds reduction in transport could be explained by changes in hCAT-1 protein abundance
However, in GDMd the reduced V max /K m could be explained by similar reduction in hCAT-1 protein abundance. Insulin-reduced hCAT-1 mRNA expression (~60%) was similar to this transporter's protein abundance in GDMi pregnancies. Since insulin-restoration of GDMd-increased hC-AT-1 mediated transport in HUVECs resulted from lower protein abundance due to lower transcription of SLC7A1 gene (for hCAT-1) [13] , insulin restoration of GDMi-increased hCAT-1 mediated transport may result from a similar phenomenon. Inhibition of p44/42 mapk restores GDMi-and GDMd-increased Larginine transport in the same proportion as insulin. Thus, p44/42 mapk over-activation could be responsible for these pathological conditions's associated increased transport, complementing similar results in cells from normal pregnancies in response to insulin [28, 33] GDMi EC 50 /R max )] was higher in GDMi (~18 fold) and GDMd (~13 fold), compared with vessel rings from normal pregnancies. This phenomenon could result from a lack of endothelial function since the response of vessels to CGRP was also reduced in GDMi (~10 fold). However, GDMi would be a stronger condition than GDMd generating endothelial dysfunction since CGRP response to insulin was~7 fold higher than in GDMd.
In conclusion, HUVECs from GDMi pregnancies show increased Larginine transport and NO synthesis, and reduced vascular reactivity compared with normal pregnancies. These findings are comparable to those in GDMd, suggesting that insulin therapy in pregnancy does not resolve the foetoplacental endothelial dysfunction associated with GDM pregnancies. However, since we used primary cultures of HUVECs and umbilical vein rings in vitro, our conclusions should not be taken as categorical. Insulin therapy normalizes maternal and foetal glycaemia [9, 18, 19] , but nothing is reported regarding the potential effect of this intervention on foetus wellbeing [3, 5] . Insulin therapy associates with higher frequency of complications in neonates [38] , including larger chance to be born large for gestational age [39] , larger number (~25%) of infants with one or more episodes with neonatal morbidity (neonatal asymptomatic hypoglycaemia) [40] , and polyhydramnios [41] , compared with infants born to mothers with GDMd. Since maternal insulin therapy effect in foetus development, newborn, and postnatal alterations are still unclear [3, 5, 9, 42] , maternal and neonatal complications are comparable in GDMi and GDMd [19, 39] , and insulin therapy seems not to revert GDM-associated foetoplacental endothelial dysfunction, subjecting pregnant women with GDM to insulin therapy should be taken with caution since the risk of foetal health alterations. 
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